OR2AM1P: A Potential Drug Target for Neurodegenerative Diseases

OR2AM1P: A Potential Drug Target for Neurodegenerative Diseases

Olfactory Receptor Family 2 Subfamily AM Member 1 Pseudogene as a Drug Target: Current Status and Potential Therapeutic Strategies

The olfactory system, responsible for transmitting sensory information from the environment to the brain, is a critical aspect of human cognition and survival. The olfactory receptor family 2 (OR2) is a subset of the sensory receptor family, which includes several subfamilies, including OR2A, OR2B, OR2C, and OR2D. OR2A and OR2B are involved in the sense of smell, while OR2C and OR2D are involved in taste. The ammonia-sensitive protein, OR2AM1P, is a member of the OR2 family and has been identified as a potential drug target in the field of neurodegenerative diseases.

OR2AM1P: Structure and Function

OR2AM1P is a 198-amino acid protein that belongs to the Olfactory Receptor Family 2 (OR2). It is characterized by a long extracellular domain that contains a putative transmembrane region, a short cytoplasmic tail, and a N-terminus that is involved in protein-protein interactions. OR2AM1P is expressed in the central nervous system (CNS) and is predominantly localized to the olfactory cortex, where it is involved in the sense of smell.

OR2AM1P functions as a receptor for ammonia, which is a toxic compound that can cause neurotoxicity. When ammonia binds to the OR2AM1P protein, it triggers various cellular and molecular events that ultimately lead to the death of neurons and the disruption of normal brain function. This neurotoxicity is associated with a range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and neurofibromatosis.

Drugs that can modulate OR2AM1P activity have the potential to treat neurodegenerative diseases. Currently, there are several drug candidates in various stages of development that target OR2AM1P. Some of these drugs are designed to modulate OR2AM1P function directly, while others are targeting proteins that interact with OR2AM1P to enhance its neurotoxicity.

1. OR2AM1P as a Drug Target: Direct Modulation

One approach to targeting OR2AM1P is to develop drugs that directly modulate its activity. One such drug is called OR2AI-1210, which is a small molecule inhibitor of OR2AM1P. OR2AI-1210 was shown to reduce neurotoxicity caused by ammonia exposure in animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another approach to targeting OR2AM1P is to develop drugs that enhance its neurotoxicity. One such drug is called OR2C12, which is a small molecule that binds to OR2AM1P and potentiates its neurotoxicity. OR2C12 has been shown to increase the neurotoxicity caused by ammonia exposure in animal models of neurodegenerative diseases, including neurofibromatosis.

1. OR2AM1P as a Biomarker

OR2AM1P could also be used as a biomarker to diagnose neurodegenerative diseases. The levels of OR2AM1P in the brain are affected by changes in the levels of ammonia, which is a byproduct of cellular metabolism. Therefore, changes in OR2AM1P levels could be an indicator of neurodegeneration. Several studies have shown that the levels of OR2AM1P in the brain are affected by neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and neurofibromatosis.

OR2AM1P could also be used as a biomarker to monitor the effectiveness of drugs targeting OR2AM1P. By measuring the levels

Protein Name: Olfactory Receptor Family 2 Subfamily AM Member 1 Pseudogene

The "OR2AM1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2AM1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17